- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
[VIRTUAL] Synergy between kinase inhibitors and antibodies enables upfront prevention of recurring secondary resistance in EGFR-mutated lung cancer. () - May 30, 2021 - Abstract #EACR2021EACR_1728;
Mechanistically, combinations of 2XmAbs and TKIs induced downregulation of receptor kinases previously implicated in resistance to TKIs (e.g., MET and AXL), as well as blocking pathways essential for mitosis (e.g., FOXM1). Conclusion First line treatments with combinations of kinase inhibitors and antibodies are effective in preventing TKI resistance in animal models of lung cancer and might represent a long term solution for EGFR positive NSCLC patients
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: ILF3 is a substrate of SPOP for regulating serine biosynthesis in colorectal cancer. (Pubmed Central) - May 28, 2021
Taken together, deregulation of ILF3 via the EGF-ERK signaling plays an important role in systemic serine metabolic reprogramming and confers a predilection toward CRC development. Our findings indicate that clinical evaluation of SGOC inhibitor is warranted for CRC patients with ILF3 overexpression.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Effectiveness of Vigna unguiculata seed extracts in preventing colorectal cancer. (Pubmed Central) - May 27, 2021
Furthermore, the extracts showed the ability to reduce the level of Epidermal Growth Factor Receptor (EGFR) phosphorylation in E705, DiFi and SW480 cell lines and to lower the EC50 of a CRC common drug, cetuximab, on E705 and DiFi lines from 161.7 ng mL to 0.06 ng mL and from 49.5 ng mL to 0.2 ng mL respectively...A Bowman-Birk protease inhibitor was identified within the protein fraction and was supposed to be the main active component. These findings confirm the importance of a legume-based diet to prevent the outbreak of many CRC and to reduce the amount of drug administered during a therapeutic cycle.
- |||||||||| sapitinib (AZD8931) / AstraZeneca, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: Exploring the radiosensitizing potential of AZD8931: a pilot study on the human LoVo colorectal cancer cell line. (Pubmed Central) - May 25, 2021
This radiosensitizing action by AZD8931 mainly occurred by markedly reducing cell cycle progression into S phase, the most radioresistant phase of cell cycle, secondly by inducing apoptosis and reducing clonogenic survival. Our results show that AZD8931 increases IR efficacy in LoVo cells, suggesting that it works as a potent radiosensitizer, even more efficient than Gefitinib and Cetuximab, opening new pathways of investigation for further in vitro and in vivo studies aimed at confirming its potential to improve local radiotherapy in CRC.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Differential regulation of extracellular matrix proteins in three recurrent liver metastases of a single patient with colorectal cancer. (Pubmed Central) - May 25, 2021
Despite surgical resection of the primary CRC and adjuvant chemotherapy plus cetuximab treatment, the patient developed three metachronous CRLM which occurred consecutively after 9, 21 and 31 months...These data may reflect an ascending trend of malignancy from the first to the third metachronous colorectal cancer liver metastasis. Additionally, the results indicate different ECM phenotypes for recurrent metachronous metastasis, associated with different grades of malignancy and highlights the importance of individual analysis of molecular features in different, consecutive metastatic events in a single patient.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Circulating Tumor Cells: Novel circulating tumor cell-detection chip combining conventional podoplanin and EGFR antibodies for all histological malignant pleural mesothelioma. (Pubmed Central) - May 25, 2021
To overcome this limitation, a new CTC-detection chip was developed by combining the conventional podoplanin antibody (clone: NZ-1.2) with an epidermal growth factor receptor (EGFR)-targeted antibody (cetuximab)...In epithelioid MPM, the Cocktail-chip achieved a CTC-detection efficiency equivalent to that in the conventional NZ-1.2-chip. The Cocktail-chip enabled sensitive CTC detection of all histological MPM, including the non-epithelioid subtype, which may provide a foundation for the diagnosis, treatment, and prognosis of MPM progression.
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, MSi-H Biomarker, IO biomarker: General treatment for metastatic colorectal cancer: From KEYNOTE 177 study. (Pubmed Central) - May 25, 2021
In this context, recently published randomized phase III clinical trials tested the efficacy and safety of immunotherapy and traditional chemotherapy with or without targeted drugs as first-line treatment for patients with MSI-H/dMMR mCRC. Here, we briefly analyze this article and further discuss immune monotherapy or double immunotherapy for patients with MSI-H/dMMR mCRC, the immunotherapy for patients with BRAF V600E mutant mCRC, and the immunotherapy for patients with microsatellite stable mCRC.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, IO biomarker: Reovirus enhances cytotoxicity of natural killer cells against colorectal cancer via TLR3 pathway. (Pubmed Central) - May 22, 2021
Pembrolizumab either as monotherapy or in combination with chemotherapy offers substantial survival gains for patients with R/M HNSCC at small additional costs, making it a cost-effective treatment versus cetuximab + platinum + 5-FU in Argentina. This study demonstrated that combination treatment of reovirus-activated NK cells with cetuximab synergistically enhances their anti-tumor cytotoxicity, suggesting a strong candidate strategy for clinical treatment of CRC.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Targeted camptothecin delivery via silicon nanoparticles reduces breast cancer metastasis. (Pubmed Central) - May 20, 2021
Actively targeted CPT-loaded pSiNP led to a reduction of orthotopic primary tumor growth, increased survival rate and significant decrease in hTEBC and murine lung, liver and bone metastases. This study demonstrates that targeted delivery via pSiNP is an effective approach to employ CPT and other potent anti-cancer compounds with poor pharmacokinetic profiles in cancer therapy.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Journal, Tumor microenvironment: Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3-CD8+ T cells. (Pubmed Central) - May 20, 2021
In this study, we developed an Erbitux-based IL-21 tumor-targeting fusion protein (Erb-IL21) to prolong the half-life and improve the antitumor efficacy of IL-21...Furthermore, Erb-IL21 overcame checkpoint blockade resistance in mice with advanced tumors. Our study reveals that Erb-IL21 can target IL-21 to tumors and maximize the antitumor potential of checkpoint blockade by expending a subset of tumor antigen-specific CD8+ T cells to achieve effective tumor control.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Evaluation of a Comprehensive Skin Toxicity Program for Patients Treated With Epidermal Growth Factor Receptor Inhibitors at a Cancer Treatment Center. (Pubmed Central) - May 20, 2021
The Skin Toxicity Evaluation Protocol With Panitumumab trial found reduced incidence of skin toxicity and quality of life impairment with preemptive use of doxycycline hyclate, topical corticosteroids, moisturizers, and sunscreen, demonstrating the benefit of prophylactic treatment for skin toxicity...From 2012 to 2017, preemptive tetracycline use (13 of 29 [45%] to 30 of 42 [71%]; P = .02) and topical corticosteroid use (2 of 29 [7%] to 24 of 42 [57%]; P < .001) increased and topical antibiotic use (23 of 29 [79%] to 18 of 42 [43%]; P = .002) decreased...Patients prescribed prophylactic treatment were 94% less likely to require a first rescue treatment for rash (adjusted odds ratio, 0.06; 95% CI, 0.02-0.16; P < .001), 74% less likely to require a second rescue treatment for rash (adjusted odds ratio, 0.26; 95% CI, 0.08-0.83; P = .02), and 79% less likely to experience a cetuximab dose change or interruption (adjusted odds ratio, 0.21; 95% CI, 0.06-0.81; P = .02) than patients not prescribed prophylactic treatment, adjusting for treatment site and year. Dermatologists can add value to oncology care by raising awareness of appropriate treatment options and increasing adherence to evidence-based prophylaxis protocols for EGFRi-associated rash, which is associated with decreased interventions and toxicity-associated chemotherapy interruptions.
- |||||||||| Campath (alemtuzumab) / Sanofi, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: The blood endothelial cell chamber - An innovative system to study immune responses in drug development. (Pubmed Central) - May 20, 2021
In contrast, bacterial endotoxin demonstrated a clear innate cytokine response, defined by TNFα, IL-6 and IL-1β release, accompanied with a strong recruitment of CD14CD16 cells. Therefore, the blood endothelial cell chamber model is presented as a valuable in vitro tool to investigate therapeutic monoclonal antibodies with respect to cytokine release and vascular immune cell recruitment.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Etiologic Role of Kinases in the Progression of Human Cancers and Its Targeting Strategies. (Pubmed Central) - May 20, 2021
Tyrosine kinase inhibitors are compounds that inhibit tyrosine kinases and effective in targeting angiogenesis and blocking the signaling pathways of oncogenes. Small molecule tyrosine kinase inhibitors like afatinib, erlotinib, crizotinib, gefitinib, and cetuximab are shown to a selective cut off tactic toward the constitutive activation of an oncogene in tumor cells, and thus contemplated as promising therapeutic approaches for the diagnosis of cancer and malignancies.
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial completion date, Metastases: SWOG S0819: S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (clinicaltrials.gov) - May 19, 2021
P3, N=1333, Active, not recruiting,
Small molecule tyrosine kinase inhibitors like afatinib, erlotinib, crizotinib, gefitinib, and cetuximab are shown to a selective cut off tactic toward the constitutive activation of an oncogene in tumor cells, and thus contemplated as promising therapeutic approaches for the diagnosis of cancer and malignancies. Trial completion date: Dec 2021 --> Dec 2022
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Gilotrif (afatinib) / Boehringer Ingelheim
Trial completion date, Metastases: S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer (clinicaltrials.gov) - May 19, 2021
P2/3, N=174, Active, not recruiting,
Trial completion date: Dec 2021 --> Dec 2022 Trial completion date: Mar 2021 --> Mar 2022
- |||||||||| feladilimab (GSK3359609) / GSK
Phase classification, Trial completion date, Trial primary completion date, Combination therapy, Metastases: GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors (clinicaltrials.gov) - May 19, 2021
P1/2, N=26, Active, not recruiting,
Trial completion date: Mar 2021 --> Mar 2022 Phase classification: P2 --> P1/2 | Trial completion date: Jul 2021 --> Aug 2022 | Trial primary completion date: Jul 2021 --> Aug 2022
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Global Trends in Anaphylaxis Epidemiology and Clinical Implications. (Pubmed Central) - May 15, 2021
Studying regional patterns of anaphylaxis to certain triggers have provided valuable insights into susceptibility and sensitizing events: for example, the link between the monoclonal antibody cetuximab and allergy to mammalian meat. Likewise, data from published fatality registers can identify potentially modifiable risk factors which can be used to inform clinical practice, such as prevention of delayed epinephrine administration, correct posturing during anaphylaxis, special attention to populations at risk (such as the elderly on multiple medications) and use of venom immunotherapy in individuals at risk of insect-related anaphylaxis.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Litmus-Body: a Molecularly Targeted Sensor for Cell-Surface pH Measurements. (Pubmed Central) - May 15, 2021
The sensor was further validated for use on live cells and shown to be specific to the protein of interest. In complex with our Litmus-body, Cetuximab therapeutic antibody retained its functionality in binding and inhibiting ligand interaction of its target epidermal growth factor receptor (EGFR), triggering receptor-mediated endocytosis that allowed tracking of local pH from the cell surface through the endocytic pathway.
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal, MSi-H Biomarker, IO biomarker: Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience. (Pubmed Central) - May 15, 2021
In complex with our Litmus-body, Cetuximab therapeutic antibody retained its functionality in binding and inhibiting ligand interaction of its target epidermal growth factor receptor (EGFR), triggering receptor-mediated endocytosis that allowed tracking of local pH from the cell surface through the endocytic pathway. This study provides an overview of genetic alterations in Chinese ICC patients and indicates the potential clinical implications for NGS-based personalized therapies.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal, Checkpoint inhibition, Tumor Mutational Burden, BRCA Biomarker, PD(L)-1 Biomarker, IO biomarker: Efficacy of a programmed death-1 checkpoint inhibitor in a case of cutaneous squamous cell carcinoma harboring mutations of TP53 and BRCA2. (Pubmed Central) - May 15, 2021
This report describes an 87-year-old woman with recurrent cSCC that was initially responsive to cetuximab (the monoclonal antibody against epithelial growth factor receptor) but eventually became refractory to cetuximab and multiple subsequent salvage chemotherapy regimens...Because of the high mutation burden of her neoplasm (35.2 mutations per megabase), we treated her with a programmed death-1 (PD-1) checkpoint inhibitor, pembrolizumab, for 10 months...This is the first reported case of heterozygous deletion of BRCA2 in cSCC. The high mutation burden and BRCA2 mutation might explain why this tumor was highly sensitive to anti-PD-1 treatment.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Quenched cetuximab conjugate for fast fluorescence imaging of EGFR-positive lung cancers. (Pubmed Central) - May 15, 2021
The ON-Cetuximab-treated mice expressed strong fluorescence throughout their body at 8 h post-injection; therefore, lung tumor sites could not be discriminated using fluorescence imaging. These results confirm the benefits of Q-Cetuximab for image-guided precision surgery of EGFR-positive lung cancers.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Myocardial Metastasis of Tongue Cancer: A Rare Localization. (Pubmed Central) - May 15, 2021
CONCLUSIONS This case presents a very rare diagnosis as well as some unique features, including the intramyocardial localization, the absence of symptoms, and electrocardiogram abnormalities. Our report shows the relevance of imaging techniques in defining even the most unusual clinical findings, and it emphasizes the significance of early recognition of cardiac masses in order to identify the appropriate medical or surgical therapy for patients.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Differential effects of epidermal growth factor receptor inhibitors in a single patient with neuropathic pain. (Pubmed Central) - May 15, 2021
A 52-year-old man was treated with the EGFR-I cetuximab in a trial of severe NP...On pain recurrence after the trial, he was prescribed the oral EGFR-Is erlotinib, gefitinib, and lapatinib without relief...This is the first reported observation of differential effects of EGFR-Is on NP in the same patient and the first report describing NP relief with afatinib. Further understanding of the underlying pathophysiology could lead to development of EGFR-Is specifically targeting NP.
|
